Cytomx Therap (CTMX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov10

Cantor Fitzgerald Maintains Buy Rating on CytomX Therapeutics

16:48

Nov7

Cytomx Therap released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 5.963 M (forecast USD 11.5 M), actual EPS USD -0.0899 (forecast USD -0.0495)

00:00

Cytomx Therap released FY2025 9 Months Earnings on November 6 After-Market EST, Actual Revenue USD 75.54 M, Actual EPS USD 0.1788

00:00

Oct30

Cytomx Therap to Release FY2025 Q3 Earnings on November 6 After-Market (EST), Forecast Revenue USD 11.5M, EPS USD -0.0495

00:06

Oct28

Analyst Biegler Continues to Cover CytomX Therapeutics

10:51

Oct14

Biegler Recommends Paying Attention to Healthcare Stocks Like CytomX Therapeutics

16:36

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 5.963 M, Net Income -14.23 M, EPS -0.0899

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 18.66 M, Net Income -154 K, EPS -0.0011

May12

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 50.92 M, Net Income 23.53 M, EPS 0.27

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change